Skip to content

Geron GERN Current Debt

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.31B-35.1%
Incyte logo
IncyteINCY
$4.41M-1.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350M+4.2%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$1.03B+3,224%
Gilead Sciences logo
Gilead SciencesGILD
$1.31B-53.2%
Eli Lilly logo
Eli LillyLLY
$4B-0.4%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's current debt?
Geron (GERN) reported current debt of $11.93M in Q1 2026.
What is the long-term trend for Geron's current debt?
Over 2 years (2022 to 2024), Geron's current debt has grown at a -100.0% compound annual growth rate (CAGR), from $20.95M to $0.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.